NeoGenomics (NEO) Resumen de Acciones
NeoGenomics, Inc. explota una red de laboratorios de análisis centrados en el cáncer en Estados Unidos y el Reino Unido. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 0/6 |
| Crecimiento futuro | 0/6 |
| Rendimiento pasado | 0/6 |
| Salud financiera | 4/6 |
| Dividendos | 0/6 |
NEO Community Fair Values
Create NarrativeSee what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Competidores de NeoGenomics, Inc.
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | US$16.57 |
| Máximo en las últimas 52 semanas | US$16.60 |
| Mínimo de 52 semanas | US$5.65 |
| Beta | 1.73 |
| Cambio en 1 mes | 17.43% |
| Variación en 3 meses | 91.34% |
| Cambio de 1 año | 185.69% |
| Variación en 3 años | 17.85% |
| Variación en 5 años | -61.02% |
| Variación desde la OPV | 537.31% |
Noticias y actualizaciones recientes
Actualización de narrativa • Aug 05
NEO: New Prostate Diagnostic Will Support Future Repricing
Analysts have lifted their price target on NeoGenomics from about $16.22 to roughly $19.72, citing updated fair value estimates and expectations for a higher future P/E multiple, while keeping revenue growth and profit margin assumptions broadly similar. What’s in the News for NeoGenomics NeoGenomics updated full year 2026 guidance and now expects consolidated revenue of US$802 million to US$806 million, compared with prior guidance of US$797 million to US$803 million.Actualización de narrativa • Jul 22
NEO: New Prostate Diagnostic And Compliance Resolution Will Support Future Repricing
Analysts have modestly raised their price target on NeoGenomics to $16.22 from $15.06, citing updated assumptions for fair value, profit margin, and future P/E that support a slightly higher valuation framework. What’s in the News for NeoGenomics NeoGenomics launched PTEN IHC CDx, described as the first FDA approved immunohistochemistry companion diagnostic test for prostate adenocarcinoma, to identify PTEN protein loss in patients who may be eligible for AstraZeneca’s TRUQAP (capivasertib).Recent updates
Actualización de narrativa • Aug 05
NEO: New Prostate Diagnostic Will Support Future Repricing
Analysts have lifted their price target on NeoGenomics from about $16.22 to roughly $19.72, citing updated fair value estimates and expectations for a higher future P/E multiple, while keeping revenue growth and profit margin assumptions broadly similar. What’s in the News for NeoGenomics NeoGenomics updated full year 2026 guidance and now expects consolidated revenue of US$802 million to US$806 million, compared with prior guidance of US$797 million to US$803 million.Actualización de narrativa • Jul 22
NEO: New Prostate Diagnostic And Compliance Resolution Will Support Future Repricing
Analysts have modestly raised their price target on NeoGenomics to $16.22 from $15.06, citing updated assumptions for fair value, profit margin, and future P/E that support a slightly higher valuation framework. What’s in the News for NeoGenomics NeoGenomics launched PTEN IHC CDx, described as the first FDA approved immunohistochemistry companion diagnostic test for prostate adenocarcinoma, to identify PTEN protein loss in patients who may be eligible for AstraZeneca’s TRUQAP (capivasertib).
Actualización de narrativa • Jul 08
NEO: Strong Testing Momentum Will Be Tempered By Rich Earnings Multiple
Analysts have adjusted their price target for NeoGenomics from $13.00 to $11.00. They cite updated assumptions on the discount rate, revenue growth, profit margin, and future P/E ratio, which they believe more accurately reflect the stock's risk and return profile.
Actualización de narrativa • Jun 24
NEO: Debt Refinancing And Buybacks Will Support Long Term Upside
Analysts have trimmed their price target on NeoGenomics to about $23.01 from roughly $23.43 as they factor in updated assumptions around discount rates, revenue growth, profit margins, and a much higher future P/E. Taken together, these changes point to a slightly lower fair value estimate for the stock.Artículo de análisis • Jun 17
NeoGenomics (NEO) Stock Could Be 30.3% Undervalued on Its PanTracer Growth Narrative
NeoGenomics (NEO) is back on investor radars after recent trading showed sharp short term swings, with the stock down over the past week but up strongly over the past month and past 3 months. See our latest analysis for NeoGenomics. Looking past the latest pullback, NeoGenomics has a 1 year total shareholder return of 50.07% despite a year to date share price decline of 10.80%. This suggests recent momentum has cooled after a strong rebound over the past quarter. If the recent swings in...Actualización de narrativa • Jun 09
NEO: Expanded Epic Access And Medicare Coverage Will Drive Future Repricing
Analysts have adjusted their price target on NeoGenomics to $15.06. The update reflects tweaks to assumptions around the discount rate, long term profit margin and future P/E, while leaving the implied fair value estimate unchanged.Actualización de narrativa • May 26
NEO: Expanded Test Access And Medicare Coverage Will Support Future Repricing
Analysts have raised their price target on NeoGenomics to $15.06, up from $14.19, citing updated assumptions around discount rates, profit margins, and future P/E expectations. What's in the News Updated full year 2026 revenue guidance to a range of US$797 million to US$803 million, compared with prior guidance of US$793 million to US$801 million, while maintaining an expected net loss of US$63 million to US$50 million and net loss per diluted share of US$0.48 to US$0.38 (Corporate guidance) Oncology testing portfolio made available through Epic Aura, allowing oncologists and health systems across the United States to order tests and view results directly within Epic electronic health records.Actualización de narrativa • May 01
NEO: Expanded Test Access And Coverage Will Support Long Term Upside
Analysts have revised their fair value estimate for NeoGenomics from $17.00 to about $23.43. This change reflects updated assumptions for long term revenue growth, profit margins, and a higher future P/E multiple.Actualización de narrativa • Apr 17
NEO: Medicare Test Coverage Will Support Bullish Repricing Through 2026 Guidance
Analysts have trimmed their price target on NeoGenomics from about $14.81 to roughly $14.19, citing updated assumptions for fair value, revenue growth, profit margin and future P/E that modestly reset expectations while keeping the broader thesis intact. What's in the News PanTracer LBx received coverage from the Centers for Medicare & Medicaid Services’ MolDX program under LCD L38043.Actualización de narrativa • Apr 03
NEO: Expanded Genomic Test Coverage Will Support Stronger Outlook For 2026
Analysts have raised their price target on NeoGenomics from $12.00 to $13.00, citing updated assumptions for growth, profitability, discount rate, and a higher future P/E multiple. What's in the News PanTracer LBx liquid biopsy test received coverage from the Centers for Medicare & Medicaid Services’ MolDX program under LCD L38043, expanding access for Medicare patients to blood based comprehensive genomic profiling across more than 500 genes with a seven day turnaround (Key Developments).Actualización de narrativa • Mar 19
NEO: New Medicare Coverage Will Drive Bullish Repricing Through 2026 Guidance
Analysts have kept their $14.81 price target for NeoGenomics unchanged, citing stable modeled revenue growth, profit margins, and future P/E assumptions as the basis for maintaining their view. What's in the News Medicare, through the MolDX program, granted coverage for NeoGenomics' PanTracer LBx liquid biopsy test for plasma based genomic profiling in solid tumors, expanding access for Medicare patients to a blood based comprehensive genomic profiling assay that evaluates more than 500 genes with a seven day turnaround (Key Developments).Actualización de narrativa • Mar 05
NEO: Legal Victory And 2025–2026 Guidance Will Drive Bullish Repricing
Analysts have raised their price target on NeoGenomics from about $14.43 to roughly $14.81, citing updated views on fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. What's in the News NeoGenomics launched RaDaR ST, a circulating tumor DNA assay for molecular residual disease that uses patient specific, tumor informed panels and whole exome sequencing to track up to 48 tumor variants with an LOD95 of 11 ppm.Actualización de narrativa • Feb 19
NEO: Liquid Biopsy Expansion And Legal Win Will Support Long Term Upside
Analysts have kept their $17.00 price target for NeoGenomics unchanged, reflecting only small model tweaks to the discount rate, revenue growth assumptions, profit margin expectations, and future P/E that do not materially alter their overall view of the stock. What's in the News Issued earnings guidance for 2026 with expected consolidated revenue of US$793 million to US$801 million and a projected net loss of US$63 million to US$50 million.Actualización de narrativa • Feb 05
NEO: Fair Outlook Balances Leadership Transition Patent Win And Clinical Data
Narrative Update on NeoGenomics Analysts have lifted their implied fair value estimate for NeoGenomics to US$12.00 per share, citing updated assumptions around revenue growth, discount rate, profit margin and future P/E as the key drivers behind the new price target framework. What’s in the News NeoGenomics announced a CFO succession plan, with Abhishek Jain joining as Executive Vice President on January 12, 2026 and scheduled to become CFO on March 2, 2026, as current CFO Jeff Sherman transitions toward retirement on April 14, 2026, after completing the fiscal 2025 reporting cycle.Seeking Alpha • Jan 25
NeoGenomics: Distribution Moat In Community Oncology
Summary NeoGenomics is transitioning from a commodity diagnostic provider to a comprehensive precision oncology platform, leveraging deep relationships with community oncologists. NEO’s clinical services revenue grew 18% YoY in Q3 2025, with high-value Next Generation Sequencing now nearly one-third of clinical revenue and outpacing market growth. The upcoming RaDaR ST launch in Q1 2026 positions NEO as a fast follower in the $20B MRD market, capitalizing on its established distribution and workflow integration. NEO trades at a significant discount to sector peers on EV/Sales and P/S, offering a margin of safety if execution on MRD and margin expansion materializes. Read the full article on Seeking AlphaActualización de narrativa • Jan 22
NEO: Legal Win And 2025 Guidance Will Drive Bullish Repricing
Analysts have raised their price target for NeoGenomics to about US$14.43 from roughly US$13.44, citing updated assumptions for the discount rate, revenue growth, profit margin, and future P/E that refine their view of the company’s long-term earnings power. What's in the News Issued preliminary unaudited guidance for the fourth quarter of 2025 with expected total revenue of about US$190 million and year over year growth of 11%, and full year 2025 revenue of about US$727 million with year over year growth of 10% (company guidance).Actualización de narrativa • Jan 08
NEO: Future Liquid Biopsy Data Pipeline Will Support Stronger Long Term Outlook
Analysts have lifted their fair value estimate for NeoGenomics from US$14.00 to US$17.00. They cite updated assumptions around revenue growth, profit margins and future P/E that they believe better reflect the company’s outlook.Actualización de narrativa • Dec 14
NEO: Upcoming Trial Readouts And Guidance Will Drive Bullish Repricing
Narrative Update on NeoGenomics Analysts have modestly raised their price target on NeoGenomics to approximately 13.44 dollars from about 13.17 dollars, citing slightly stronger long term revenue growth expectations and a marginally higher future earnings multiple, despite a nearly unchanged discount rate and profit margin outlook. What's in the News Upcoming SABCS 2025 presentations will showcase RaDaR 1.0 ctDNA data from the SURVIVE HERoes Phase III trial and CLEVER study in early breast cancer, supporting ctDNA guided surveillance and earlier intervention strategies (company announcement).Actualización de narrativa • Nov 29
NEO: Upcoming Research and Earnings Guidance Will Shape Market Expectations
Analysts have slightly raised their price target for NeoGenomics from $13.06 to $13.17 per share. This reflects updated assessments of future profitability and market growth potential.Actualización de narrativa • Nov 15
NEO: Upcoming Research Presentations Are Expected To Drive Solid Tumor Detection Momentum
Analysts have raised their fair value estimate for NeoGenomics from $11.72 to $13.06. This change is attributed to slightly improved revenue growth projections, as well as a modest increase in profit margins and future valuation multiples.Actualización de narrativa • Nov 01
NEO: Upcoming Research Presentations Will Accelerate Future Oncology Diagnostic Opportunities
Analysts have raised their price target for NeoGenomics from $10.44 to $11.72 per share. They cite marginal improvements in projected revenue growth and profit margin estimates.Actualización de narrativa • Oct 18
Advanced Oncology Diagnostics And NGS Capabilities Will Create Future Opportunities
Analysts have raised their price target for NeoGenomics from $9.78 to $10.44 per share, citing slightly improved revenue growth projections and a modestly higher future price-to-earnings multiple. What's in the News NeoGenomics announced the presentation of key MRD assay data, including results from interventional therapy trials, at the upcoming ESMO Congress 2025 in Berlin.Actualización de narrativa • Aug 30
Advanced Oncology Diagnostics And NGS Capabilities Will Create Future Opportunities
The higher analyst price target for NeoGenomics reflects an expansion in its future P/E multiple despite stable revenue growth forecasts, resulting in a revised fair value of $9.78. What's in the News U.S. District Court invalidated certain Natera patents asserted against NeoGenomics’ RaDaR v1.1 test, but the decision does not affect the '035 patent that previously led to a permanent injunction on RaDaR v1.0. NeoGenomics launched NEO PanTracer LBx, a blood-based comprehensive genomic profiling (CGP) test targeting the expanding liquid biopsy market and enhancing its pan-solid tumor CGP portfolio.Artículo de análisis • Aug 27
Would NeoGenomics (NASDAQ:NEO) Be Better Off With Less Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Artículo de análisis • Jul 30
Market Cool On NeoGenomics, Inc.'s (NASDAQ:NEO) Revenues Pushing Shares 27% Lower
NeoGenomics, Inc. ( NASDAQ:NEO ) shareholders won't be pleased to see that the share price has had a very rough month...Artículo de análisis • May 23
Take Care Before Jumping Onto NeoGenomics, Inc. (NASDAQ:NEO) Even Though It's 25% Cheaper
Unfortunately for some shareholders, the NeoGenomics, Inc. ( NASDAQ:NEO ) share price has dived 25% in the last thirty...
Nueva narrativa • Mar 23
PanTracer Launch And MRD Collaboration Will Strengthen Future Cancer Testing Leadership
NeoGenomics' strategic investments and collaborations are expected to enhance customer experiences, boost test volumes, and strengthen competitive positioning in MRD monitoring and Heme testing.Artículo de análisis • Mar 08
NeoGenomics, Inc.'s (NASDAQ:NEO) Stock Retreats 28% But Revenues Haven't Escaped The Attention Of Investors
Unfortunately for some shareholders, the NeoGenomics, Inc. ( NASDAQ:NEO ) share price has dived 28% in the last thirty...Seeking Alpha • Feb 28
NeoGenomics: Decent Fundamentals, But Still Overvalued
Summary NeoGenomics is rated a Hold due to the intrinsic value being lower than the current price, and the company's negative net income and FCF. Despite revenue growth and increasing clinical volume, NeoGenomics missed revenue estimates, causing a 15.50% drop in the stock price. NeoGenomics shows promising long-term growth potential with rising cancer cases and improving ROIC, but negative profitability is a concern. Intrinsic value calculations using the Graham's Formula and DCF model suggest the stock may not yet be done falling. I am recommending caution. Read the full article on Seeking AlphaArtículo de análisis • Feb 18
Here's Why NeoGenomics (NASDAQ:NEO) Can Afford Some Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Rentabilidad de los accionistas
| NEO | US Healthcare | Mercado US | |
|---|---|---|---|
| 7D | 8.4% | -0.2% | 4.2% |
| 1Y | 185.7% | 40.5% | 20.6% |
Rentabilidad vs. Industria: NEO superó a la industria US Healthcare, que obtuvo un rendimiento del 40.5% el año pasado.
Rentabilidad vs. Mercado: NEO superó al mercado US, que obtuvo un rendimiento del 20.6% el año pasado.
Volatilidad de los precios
| NEO volatility | |
|---|---|
| NEO Average Weekly Movement | 9.1% |
| Healthcare Industry Average Movement | 7.2% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.1% |
Precio estable de las acciones: NEO no ha tenido una volatilidad de precios significativa en los últimos 3 meses en comparación con el mercado US.
Volatilidad a lo largo del tiempo: La volatilidad semanal de NEO (9%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2001 | 2,500 | Tony Zook | www.neogenomics.com |
NeoGenomics, Inc. gestiona una red de laboratorios de análisis centrados en el cáncer en Estados Unidos y el Reino Unido. La empresa ofrece servicios de análisis a hospitales, centros académicos, patólogos, oncólogos, médicos, empresas farmacéuticas y laboratorios clínicos. También ofrece servicios de citogenética para estudiar los cromosomas normales y anormales y su relación con las enfermedades; servicios de hibridación fluorescente in situ para detectar y localizar la presencia o ausencia de secuencias de ADN y genes específicos en los cromosomas; servicios de citometría de flujo para medir las características de las poblaciones celulares; y servicios de inmunohistoquímica e imagen digital para localizar proteínas celulares en secciones de tejido, así como para permitir a los clientes visualizar los portaobjetos escaneados y realizar análisis cuantitativos de diversas tinciones.
Resumen de fundamentos de NeoGenomics, Inc.
| Estadísticas fundamentales de NEO | |
|---|---|
| Capitalización bursátil | US$2.13b |
| Beneficios(TTM) | -US$51.88m |
| Ingresos (TTM) | US$766.30m |
2.8x
Ratio precio-ventas (PS)-41.0x
Ratio precio-beneficio (PE)¿Está NEO sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de NEO | |
|---|---|
| Ingresos | US$766.30m |
| Coste de los ingresos | US$429.76m |
| Beneficio bruto | US$336.53m |
| Otros gastos | US$388.41m |
| Beneficios | -US$51.88m |
Últimos beneficios comunicados
Jun 30, 2026
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -0.40 |
| Margen bruto | 43.92% |
| Margen de beneficio neto | -6.77% |
| Ratio deuda/patrimonio | 47.6% |
¿Cómo se ha desempeñado NEO a largo plazo?
Ver rendimiento histórico y comparativaAnálisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/08/09 06:53 |
| Precio de las acciones al final del día | 2026/08/07 00:00 |
| Beneficios | 2026/06/30 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
NeoGenomics, Inc. está cubierta por 25 analistas. 12 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Bruce Jackson | Benchmark Company |
| Raymond Myers | Benchmark Company |
| Michael Ryskin | BofA Global Research |